The company says growth is coming from all sales regions and product lines, with its allergy immunotherapy tablets as the main driver. The expected EBIT margin has been raised to around 27%, from around 26%, mainly reflecting operating leverage from the higher revenue.

This is ALK’s third outlook increase this year, following an upgrade with its Q1 report in May and a raised revenue range in August.